Lipids, An Issue of Endocrinology and Metabolism Clinics, 1st Edition
Author :
By Donald A. Smith, MD, MPH
This issue of the Endocrinology and Metabolism Clinics of North America, devoted to the topic of lipids, provides the most essential updates and new treatments in the field. The following subject matter is addressed: assessment of the effectiveness
...view more
This issue of the Endocrinology and Metabolism Clinics of North America, devoted to the topic of lipids, provides the most essential updates and new treatments in the field. The following subject matter is addressed: assessment of the effectiveness of advanced lipoprotein testing; rosk scores for prediction of cardiovascular outcomes; lifestyle and dietary approaches to lowering LDC-cholesterol and triglycerides, and raising HDL-cholesterol; comparative efficacy and safety of statins, ezetimibe, bile acide binders, and combinations for lowering LDL-C; alternative therapies for reducing LDL-C, including intestinal bypass, and new medications such as squalene synthase inhibitors, ApoB antisense oligonucleotides, small interfering RNA’s of Apo B and proprotein convertase subtilism kexin 9 (PCSK9); myopathic problems of statins; pharmacologic management of hypertriglyceridemia, including fibric acids, niacin, and fish oils; new treatments for raising LDL cholesterol, lipid management in special patient populations, including pediatric, geriatric, and patients with HIV; lipid management in renal failure, hemodialysis, and transplantation.
This issue of the Endocrinology and Metabolism Clinics of North America, devoted to the topic of lipids, provides the most essential updates and new treatments in the field. The following subject matter is addressed: assessment of the effectiveness of advanced lipoprotein testing; rosk scores for prediction of cardiovascular outcomes; lifestyle and dietary approaches to lowering LDC-cholesterol and triglycerides, and raising HDL-cholesterol; comparative efficacy and safety of statins, ezetimibe, bile acide binders, and combinations for lowering LDL-C; alternative therapies for reducing LDL-C, including intestinal bypass, and new medications such as squalene synthase inhibitors, ApoB antisense oligonucleotides, small interfering RNA’s of Apo B and proprotein convertase subtilism kexin 9 (PCSK9); myopathic problems of statins; pharmacologic management of hypertriglyceridemia, including fibric acids, niacin, and fish oils; new treatments for raising LDL cholesterol, lipid management in special patient populations, including pediatric, geriatric, and patients with HIV; lipid management in renal failure, hemodialysis, and transplantation.
Author Information
By Donald A. Smith, MD, MPH, Mount Sinai School of Medicine
https://www.asia.elsevierhealth.com/lipids-an-issue-of-endocrinology-and-metabolism-clinics-9781437704723.html299452Lipids, An Issue of Endocrinology and Metabolism Clinicshttps://www.asia.elsevierhealth.com/media/catalog/product/https://www.asia.elsevierhealth.com/media/catalog/product/placeholder/default/generic_item_image_123x160_1_1.png74.2498.99USDInStock/Clinics/Medicine & Surgery/Endocrinology/Medicine/Endocrinology/Clinics/Clinics/Medicine/Endocrinology/Japan Titles43887254335179505460650546665255041525989252631601418269243350884886536505455351451205259833This issue of the Endocrinology and Metabolism Clinics of North America, devoted to the topic of lipids, provides the most essential updates and new treatments in the field. The following subject matter is addressed: assessment of the effectiveness of advanced lipoprotein testing; rosk scores for prediction of cardiovascular outcomes; lifestyle and dietary approaches to lowering LDC-cholesterol and triglycerides, and raising HDL-cholesterol; comparative efficacy and safety of statins, ezetimibe, bile acide binders, and combinations for lowering LDL-C; alternative therapies for reducing LDL-C, including intestinal bypass, and new medications such as squalene synthase inhibitors, ApoB antisense oligonucleotides, small interfering RNA’s of Apo B and proprotein convertase subtilism kexin 9 (PCSK9); myopathic problems of statins; pharmacologic management of hypertriglyceridemia, including fibric acids, niacin, and fish oils; new treatments for raising LDL cholesterol, lipid management in special patient populations, including pediatric, geriatric, and patients with HIV; lipid management in renal failure, hemodialysis, and transplantation. This issue of the Endocrinology and Metabolism Clinics of North America, devoted to the topic of lipids, provides the most essential updates and new treatments in the field. The following subject matter is addressed: assessment of the effectiveness of advanced lipoprotein testing; rosk scores for prediction of cardiovascular outcomes; lifestyle and dietary approaches to lowering LDC-cholesterol and triglycerides, and raising HDL-cholesterol; comparative efficacy and safety of statins, ezetimibe, bile acide binders, and combinations for lowering LDL-C; alternative therapies for reducing LDL-C, including intestinal bypass, and new medications such as squalene synthase inhibitors, ApoB antisense oligonucleotides, small interfering RNA’s of Apo B and proprotein convertase subtilism kexin 9 (PCSK9); myopathic problems of statins; pharmacologic management of hypertriglyceridemia, including fibric acids, niacin, and fish oils; new treatments for raising LDL cholesterol, lipid management in special patient populations, including pediatric, geriatric, and patients with HIV; lipid management in renal failure, hemodialysis, and transplantation.00add-to-cart97814377047232011 and earlierProfessionalBy Donald A. Smith, MD, MPH20091Book152w x 229h (6.00" x 9.00")Saunders240Mar 17, 2009IN STOCKBy <STRONG>Donald A. Smith</STRONG>, MD, MPH, Mount Sinai School of MedicineClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select